Bone Health Media

The independent intelligence platform for bone health.

The field has the science. What it's missing is the infrastructure — the measurement, analysis, and alignment architecture that turns clinical knowledge into health system action and investment.

Read the Working Papers Explore the Ecosystem

$57B

Annual direct costs of osteoporosis in the U.S.

<20%

Fracture patients who receive follow-on osteoporosis therapy

54M

Americans affected by osteoporosis or low bone mass

Age 40

When systematic bone health risk identification should begin

The Structural Gap

No one owns bone health. And it shows.

A structural failure, not a scientific one.

Unlike cardiology, oncology, or endocrinology — bone health has no dedicated medical specialty and no board certification. Clinical responsibility is dispersed across primary care, endocrinology, rheumatology, orthopedics, geriatrics, and gynecology.

The administrative layer follows clinical ownership. No clinical champion means no service line priority, no investment thesis, no infrastructure. Physicians report diverging opinions about where the main responsibility for osteoporosis management lies.

This is not a knowledge problem. Effective diagnostics and treatments exist. The gap is structural — and structural failures are solvable.

<20%

of fracture patients receive osteoporosis therapy in the year following their fracture — a gap documented worldwide

PMC Review — osteoporosis care gap

"Among women 55 and older, osteoporotic fractures account for more hospitalizations than heart attack, stroke, and breast cancer — combined."

Mayo Clinic Proceedings / US Nationwide Inpatient Sample, 2000–2011

Why Now

Something is changing. Several things, simultaneously.

The structural setup for a new vertical is in place.

Regulatory

SABRE / FDA Qualification

FDA qualified hip bone mineral density as a validated surrogate endpoint for osteoporosis drug trials — the first qualification under the 21st Century Cures Act. Trials once requiring 5+ years can now use a measurable biomarker.

December 19, 2025

Market Access

Biosimilar Entry

Competition is compressing margins on existing bone health agents, forcing payer and PBM formulary reassessment — and making treatment economically accessible at scale for the first time.

Ongoing, accelerating

Adjacent Market

GLP-1 Spillover

GLP-1 agonists affect bone mineral density. As the class scales, bone health becomes a downstream clinical and liability concern for every metabolic health stakeholder. The FDA semaglutide label now notes increased fracture risk in older adults.

$53.5B (2024) → $268B projected (2034)

Coverage Logic

Payer Cost Visibility

Post-fracture Medicare cost data is maturing. The evidence base for fracture liaison services is strengthening. Payer-level coverage logic is becoming defensible in ways it was not five years ago.

BHOF / Milliman, 2021

Demographics

Aging Demographics

Annual US fractures projected at 3.2M by 2040 — $95B+ in costs — regardless of intervention. The fracture burden will grow. The only question is whether infrastructure will be in place to address it.

BHOF / Milliman / NC Governor proclamation, 2024

Historical Parallel

We've seen this before.

Bone health is where diabetes was before the vertical catalyzed.

Dimension	Diabetes — Then	Bone Health — Now
Field structure	Fragmented, no unified infrastructure	Fragmented, no unified infrastructure
Therapy landscape	Effective treatments existed, adoption low	Effective treatments exist, adoption low
Payer perception	Chronic cost burden, low ROI	Chronic cost burden, low ROI
Measurement	No validated surrogate endpoint	BMD surrogate qualified (SABRE, Dec 2025)
Drug pipeline	Stalled — long trials, high cost	Unlocking — trial timelines now compressible
Capital	Sitting on sidelines	Sitting on sidelines
Catalysts	DCCT trial + glucometer + policy alignment	SABRE + biosimilars + GLP-1 spillover + payer data
Result	$100B+ vertical: CGM, GLP-1s, digital therapeutics	TBD — structural setup identical

Sources: DCCT trial (NEJM, 1993); GLP-1 market: Grand View Research 2024 ($53.5B → $268B by 2034); diabetes devices: MarketsandMarkets 2024; SABRE/FDA Dec 2025

About BHM

The field needs infrastructure. We're building it.

Founded on a single observation: osteoporosis affects 54 million Americans, generates $57 billion in annual direct costs, and remains systematically underdiagnosed, undertreated, and underinvested. The gap is not scientific — it is structural.

Our Mission & Story

Insight

Peer-informed working papers on systems, policy, and capital allocation — written for decision-makers, not academic audiences.

Analysis

Continuous measurement of the bone health ecosystem — capital flows, commercial activity, and field-level signals — through the BHM Index and Annual Report.

Connection

Convening the health system executives, payer leaders, investors, and industry partners who can close the gap — through the BHM Summit and Basement Tapes.

Stay connected to the field.

Working papers, ecosystem intelligence, and field updates from BHM — built for the people making decisions in bone health.